INT140414

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.64
First Reported 2006
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 25
Total Number 26
Disease Relevance 23.43
Pain Relevance 2.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (AQP4) plasma membrane (AQP4) transmembrane transport (AQP4)
cytoplasm (AQP4)
Anatomy Link Frequency
B-cell 2
plasma 1
spinal cord 1
brain 1
M-1 1
AQP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Substantia nigra 16 99.92 Very High Very High Very High
Multiple sclerosis 148 99.80 Very High Very High Very High
ischemia 16 99.68 Very High Very High Very High
Spinal cord 125 99.38 Very High Very High Very High
Dopamine 64 98.40 Very High Very High Very High
cerebral cortex 16 96.00 Very High Very High Very High
addiction 25 95.20 Very High Very High Very High
Central nervous system 84 93.28 High High
Neuritis 114 93.00 High High
Glutamate 54 92.00 High High
Disease Link Frequency Relevance Heat
Demyelinating Disease 308 99.90 Very High Very High Very High
Stroke 8 99.88 Very High Very High Very High
Disease 766 99.84 Very High Very High Very High
Neurological Disease 77 99.84 Very High Very High Very High
Cv Unclassified Under Development 16 99.68 Very High Very High Very High
Targeted Disruption 92 99.64 Very High Very High Very High
Neuromyelitis Optica 1364 99.60 Very High Very High Very High
Systemic Lupus Erythematosus 90 99.50 Very High Very High Very High
Creutzfeldt Jakob Disease 80 99.44 Very High Very High Very High
Lewy Body Disease 24 99.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The marked loss of EAAT2 described in this report parallels loss of AQP4 in lesioned NMO spinal cord tissue and contrasts with the increases in EAAT2 and AQP4 reported in both active and chronic MS lesions (20).
Positive_regulation (increases) of AQP4 in spinal cord associated with neuromyelitis optica, multiple sclerosis and spinal cord
1) Confidence 0.64 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2571922 Disease Relevance 1.09 Pain Relevance 0.61
In a previous study that included samples obtained over a period of up to five years, we could demonstrate marked variations over time regarding AQP4-Ab concentrations during remission with no general cut-off for relapse induction (though relapses were always preceded by an relative increase in AQP4-Ab levels).
Positive_regulation (increase) of AQP4 associated with recurrence
2) Confidence 0.63 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2945323 Disease Relevance 0.67 Pain Relevance 0.11
Interruption of therapy was, however, followed by clinical relapse (34, 65 and 181 days after suspension, respectively) and increase of AQP4-Ab values (2.2-, 1.4- and 7.2-fold, respectively) in all cases (Fig. 2D, F, H and J).
Positive_regulation (increase) of AQP4 associated with recurrence
3) Confidence 0.62 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.98 Pain Relevance 0
They reappeared after 251, 258, 265, 272 and 350 days, respectively, following the last application of rituximab, with slight rises in cell counts being associated with a strong increase in AQP4-Ab values (Fig. 2A, day 3168; Fig. 2B, day 1392).
Positive_regulation (increase) of AQP4
4) Confidence 0.62 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.21 Pain Relevance 0.03
AQP4 levels in microvascular endothelium increase in diseases associated with BBB disruption [94] and its absence protects the mouse brain from damages characteristic of BBB malfunctioning [58].


Positive_regulation (increase) of AQP4 in brain associated with disease
5) Confidence 0.54 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.76 Pain Relevance 0.07
In addition, the expression of AQP4 in the lesioned striatum needs to be investigated, considering that in the substantia nigra an increase in AQP4 mRNA following 6-hydroxidopamine (6-OH-DA) lesion has been observed [94].
Spec (investigated) Positive_regulation (increase) of AQP4 in substantia nigra associated with dopamine and substantia nigra
6) Confidence 0.54 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.60 Pain Relevance 0.30
Over-expression of AQP4 at the glio-vascular swollen end-feet it has been observed in the transgenic rats SOD1 [73]: these findings are in agreement with the observation that AQP4 induction in perivascular astrocytes has been correlated to BBB breakdown and could serve as a marker of BBB integrity [88].
Positive_regulation (induction) of AQP4 in astrocytes associated with targeted disruption
7) Confidence 0.54 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.82 Pain Relevance 0.06
In addiction, Lucchinetti [56] and Roemer [80] and their groups have independently performed detailed comparative study between NMO and MS lesions: in particular, in contrast to NMO, they revealed that AQP4 immunoreactivity was variable in MS lesions (AQP4 is diffusely increased in the white matter of active lesions, whereas chronic inactive lesions are devoid of AQP4).
Positive_regulation (increased) of AQP4 in white matter associated with addiction, neuromyelitis optica and multiple sclerosis
8) Confidence 0.54 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.47 Pain Relevance 0.35
This concept was already approached by Kaiser and colleagues [44], who observed a progressive loss of Kir4.1 and a slight increase in AQP4 protein in the mouse ALS model.
Positive_regulation (increase) of AQP4 associated with motor neuron diseases
9) Confidence 0.54 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.81 Pain Relevance 0.09
Immunohistochemistry revealed AQP4 immunoreactivity in cell membrane of thymoma cells from all ten thymoma specimens whereas thymic tissues from patients without thymoma or MG were negative for AQP4 immunoreactivity.
Positive_regulation (negative) of AQP4
10) Confidence 0.50 Published 2010 Journal J. Neuroimmunol. Section Body Doc Link 20728226 Disease Relevance 0.15 Pain Relevance 0
Moreover, none of the patients were only positive for M-1 AQP4-IgG and negative for M-23 AQP4-IgG, or had higher titer levels for full length AQP4.
Positive_regulation (positive) of AQP4-IgG in M-1
11) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 0.60 Pain Relevance 0
Our study confirms weaker binding of NMO-IgG to full length AQP4, resulting in a lower sensitivity for clinically definite NMO (70%) and high risk NMO (39%) patients, besides also the M-23 IgG seropositive patient with SLE associated myelitis was negative for full length AQP4-IgG.
Positive_regulation (negative) of AQP4-IgG associated with neuromyelitis optica, demyelinating disease and systemic lupus erythematosus
12) Confidence 0.50 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 1.55 Pain Relevance 0.07
However, using the new anti-AQP4 antibody assay, we showed that eight patients with NMO including the six NMO-IgG-positives were positive for anti-AQP4 antibody.
Positive_regulation (positive) of AQP4 associated with neuromyelitis optica
13) Confidence 0.50 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 17146196 Disease Relevance 1.46 Pain Relevance 0.10
In contrast, the patients with MS or other neurological disorders showed negative for anti-AQP4 antibody.
Positive_regulation (negative) of AQP4 associated with neurological disease
14) Confidence 0.50 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 17146196 Disease Relevance 0.92 Pain Relevance 0.03
In comparison to AQP4-IgG, AQP4-IgM Abs are not a reliable biomarker, although they were elevated in definite and high risk NMO patients.
Positive_regulation (elevated) of AQP4-IgM associated with neuromyelitis optica
15) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 1.18 Pain Relevance 0.14
AQP4-IgM was elevated in AQP4-IgG positive patients, however because of lower sensitivity and specificity its role as biomarker in NMO remains unclear.



Positive_regulation (elevated) of AQP4-IgM associated with neuromyelitis optica
16) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 0.92 Pain Relevance 0.11
As recent studies suggest a strong correlation of NMO-IgG titres with the clinical status of disease [24], [29] we performed serial dilutions of NMO Ig positive samples, resulting in higher titer levels of M-23 AQP4-IgG.
Positive_regulation (resulting) of AQP4-IgG associated with neuromyelitis optica and disease
17) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2864757 Disease Relevance 0.67 Pain Relevance 0
Importantly, the reappearance of even low B-cell numbers was found to be sufficient to induce an increase in AQP4-Ab values, and reoccurrence of CD19 cells was associated with a high relapse risk.
Positive_regulation (increase) of AQP4 in B-cell associated with recurrence
18) Confidence 0.45 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.54 Pain Relevance 0
In another patient with elevated AQP4-Ab levels prior to application, rituximab could not prevent clinical attacks 27 and 99 days later (Fig. 2I).


Positive_regulation (elevated) of AQP4
19) Confidence 0.45 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.84 Pain Relevance 0
However, a continuous yet slightly oscillating increase in AQP4-Ab titres was found after dose reduction, which was not followed by clinical relapse after 956 days.
Positive_regulation (increase) of AQP4 associated with recurrence
20) Confidence 0.45 Published 2008 Journal Brain Section Body Doc Link PMC2577801 Disease Relevance 0.66 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox